---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-008146"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2023-03-15T23:59:59+00:00"
generated_at: "2026-06-18T02:07:55.927858+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# 4DMT reports FY22 net loss of $107.5M; cash runway into H1 2025; pipeline advances

## Summary
- Net loss $107.5M in 2022 (vs $71.3M in 2021); revenue $3.1M (vs $18.0M) due to Roche collaboration end.
- Cash, equivalents & marketable securities $218.5M; expected to fund operations into first half 2025.
- 4D-150 wet AMD interim data: >90% reduction in anti-VEGF injections; dose exploration enrolled, phase 2 dose expansion started Jan 2023. DME IND cleared.
- 4D-710 cystic fibrosis: cohort 2 enrollment completed Feb 2023; interim data planned for Q2 2023 conference.
- 4D-310 Fabry cardiomyopathy: interim cardiac improvements shown; FDA clinical hold response expected Q1 2023.

## SEC filing metadata
- accession: 0000950170-23-008146
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2023-03-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000095017023008146/0000950170-23-008146-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000095017023008146/fdmt-20230315.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-008146
- JSON: https://secwatch.observer/filing/0000950170-23-008146.json
- Plain text: https://secwatch.observer/filing/0000950170-23-008146.txt

## Key facts
- Earnings Releases
  4D Molecular Therapeutics, Inc. reported the year ended December 31, 2022 results: revenue $3.1 million.
  - Period: the year ended December 31, 2022
  - Revenue: $3.1 million
  - Result: reported results
  source text: Total revenue was $3.1 million for 2022, as compared to $18.0 million for 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650648/000095017023008146/0000950170-23-008146-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.